Results of lung metastasectomy from breast cancer: prognostic criteria on the basis of 467 cases of the international registry of lung metastases

被引:166
作者
Friedel, G
Pastorino, U
Ginsberg, RJ
Goldstraw, P
Johnston, M
Pass, H
Putnam, JB
Toomes, H
机构
[1] Klin Schillerhoehe, Dept Thorac Surg, D-70839 Gerlingen, Germany
[2] European Inst Oncol, Dept Thorac Surg, Milan, Italy
[3] Toronto Gen Hosp, Dept Thorac Surg, Toronto, ON, Canada
[4] Wayne State Univ, Harper Hosp, Dept Surg & Oncol, Detroit, MI USA
[5] Univ Texas, MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX 77030 USA
关键词
breast cancer; lung metastases; lung metastasectomy; prognostic factors;
D O I
10.1016/S1010-7940(02)00331-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Metastatic breast cancer is still defined as an incurable disease. Although the prognosis after resection of isolated metastases to the lung is much better than after chemotherapy most oncologists and gynecologists disapprove of lung metastasectomy. Methods: In order to summarize the experience of pulmonary metastatic surgery and to achieve more relevant data by an increased number of cases, we evaluate the data of the International Registry of Lung Metastases of 467 patients having lung metastases from breast cancer with regard to long-term survival and prognostic factors. Results: In 84% a complete metastatic resection was possible. The survival rates are 38% after 5 years, 22% after 10 years, and 20% after 15 years. Prognostic factors are a disease-free interval of greater than or equal to36 months with 5-year survival of 45%, a 10-year survival of 26% and a 15-year survival of 21% (P = 0.0001), solitary lung metastasis is associated with a survival rate of 44% after 5 years and of 23% after 10 and 15 years, but this is not statistically significant compared to multiple metastases. When establishing prognostic groups as suggested by Pastorino and the International Registry of Lung Metastases based on the risk factors disease-free interval, number of metastases and complete resection the group with the best prognosis showed 5-year survival of 50%, 10- and 15-year survival of 26% with a median survival of 59 months. Conclusion: Considering the low morbidity and mortality rate, we think that lung metastasectomy today is the best treatment option in selected cases of lung metastases from breast cancer. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:335 / 344
页数:10
相关论文
共 18 条
[1]   PROGNOSTIC FACTORS FOR PROLONGED PROGRESSION-FREE SURVIVAL WITH HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL SUPPORT FOR ADVANCED BREAST-CANCER [J].
AYASH, LJ ;
WHEELER, C ;
FAIRCLOUGH, D ;
SCHWARTZ, G ;
REICH, E ;
WARREN, D ;
SCHNIPPER, L ;
ANTMAN, K ;
FREI, E ;
ELIAS, A .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (08) :2043-2049
[2]   RETRACTED: HIGH-DOSE CHEMOTHERAPY WITH HEMATOPOIETIC RESCUE AS PRIMARY-TREATMENT FOR METASTATIC BREAST-CANCER - A RANDOMIZED TRIAL (Retracted article. See vol. 19, pg. 2973, 2001) [J].
BEZWODA, WR ;
SEYMOUR, L ;
DANSEY, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (10) :2483-2489
[3]  
Bodzin G A, 1998, Chest Surg Clin N Am, V8, P145
[4]   THE CLINICAL COURSE OF BONE METASTASES FROM BREAST-CANCER [J].
COLEMAN, RE ;
RUBENS, RD .
BRITISH JOURNAL OF CANCER, 1987, 55 (01) :61-66
[5]   THE SIGNIFICANCE OF PROGNOSTIC FACTORS FOR THE RESECTION OF PULMONARY METASTASES OF BREAST-CANCER [J].
FRIEDEL, G ;
LINDER, A ;
TOOMES, H .
THORACIC AND CARDIOVASCULAR SURGEON, 1994, 42 (02) :71-75
[6]  
Friedel G, 1999, ANTICANCER RES, V19, P1593
[7]  
HEIDEMANN E, 1993, ONKOLOGIE, V16, P344
[8]  
JONAT W, 1998, ONKOLOGIE, V4, P945
[9]   LONG-TERM SURVIVAL AFTER RESECTION OF PULMONARY METASTASES FROM CARCINOMA OF THE BREAST [J].
LANZA, LA ;
NATARAJAN, G ;
ROTH, JA ;
PUTNAM, JB .
ANNALS OF THORACIC SURGERY, 1992, 54 (02) :244-248
[10]  
Martini N, 1998, Chest Surg Clin N Am, V8, P13